Osaka University

The Research Foundation for Microbial Diseases of Osaka

The Research Foundation for Microbial Diseases

Chisato Mori

Iwao Yoshida

Isao Fuke

Akihisa Takamizawa

Hiroto Okayama

Juichiro Osame

Konosuke Fukai

Keisuke Takaku

Yasuyuki Gomi

Sadao Manabe

Toyokazu Ishikawa

Rie Takahara

Disclosed is an isolated non-A, non-B hepatitis virus genomic CDNA covering the entire region of the virus gene nucleotide sequence from the 1st to 9416th nucleotides shown in FIG.,(,) through FIG.,(,) hereof, wherein the coding region is from the 333rd to 9362nd nucleotides, and the 5&prime;- and 3&prime;-noncoding sequences contain 332 nucleotides and 54 nucleotides, respectively. Part of the cDNA and an antigen polypeptide as an expression product thereof are useful as a diagnostic reagent for non-A, non-B hepatitis. The antigen polypeptide is also useful as an active ingredient for a non-A, non-B hepatitis virus vaccine.

Non-A, non-B hepatitis virus genomic cDNA and antigen polypeptide

Method for identifying attenuated chickenpox virus Oka strain or strain

Disclosed is an isolated non-A, non-B hepatitis virus genomic cDNA covering the entire region of the virus gene nucleotide sequence from the 1st to 9416th nucleotides shown in FIG. 2(1) through FIG. 2(16) hereof, wherein the coding region is from the 333rd to 9362nd nucleotides, and the 5'- and 3'- noncoding sequences contain 332 nucleotides and 54 nucleotides, respectively. Part of the cDNA and an antigen polypeptide as an expression product thereof are useful as a diagnostic reagent for non-A, non-B hepatitis. The antigen polypeptide is also useful as an active ingredient for a non-A, non-B hepatitis virus vaccine.

Disclosed is an isolated non-A, non-B hepatitis virus genomic cDNA covering the entire region of the virus gene nucleotide sequence from the 1st to 9416th nucleotides shown in FIG. 2(1) through FIG. 2(16) hereof, wherein the coding region is from the 333rd to 9362nd nucleotides, and the 5'- and 3'-noncoding sequences contain 332 nucleotides and 54 nucleotides, respectively. Part of the cDNA and an antigen polypeptide as an expression product thereof are useful as a diagnostic reagent for non-A, non-B hepatitis. The antigen polypeptide is also useful as an active ingredient for a non-A, non-B hepatitis virus vaccine.

Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide

There is provided a recombinant Marek's disease virus comprising the genomic DNA of an attenuated Marek's disease virus and a foreign gene from another source. The present recombinant virus can advantageously be used as an active ingredient for a multifunctional live vaccine, exhibiting not only the antigenicity and immunogenicity of the Marek's disease virus but also the properties ascribed to the foreign gene. Since the suitable host cell for the recombinant virus of the present invention is an avian cell which is available in a large quantity and not expensive, the recombinant virus of the present invention can be produced efficiently at low cost on a commercial scale.

Recombinant Marek's disease virus and vaccine

Growing community of inventors

Kanonji, Japan

Chisato Mori